A 28-day oral dose toxicity study enhanced to detect endocrine effects of hexabromocyclododecane in Wistar rats.
A 28-day repeated dose study in rats (OECD407) enhanced for endocrine and immune parameters was performed with hexabromocyclododecane (HBCD). Rats were exposed by daily gavage to HBCD dissolved in corn oil in 8 dose groups with doses ranging between 0 and 200 mg/kg bw per day (mkd). Evaluation consisted of dose-response analysis with calculation of a benchmark dose at the lower 95% one-sided confidence bound (BMDL) at predefined critical effect sizes (CESs) of 10-20%. The most remarkable findings were dose-related effects on the thyroid hormone axis, that is, decreased total thyroxin (TT4, BMDL 55.5 mkd at CES--10%), increased pituitary weight (29 mkd at 10%) and increased immunostaining of TSH in the pituitary, increased thyroid weight (1.6 mkd at 10%), and thyroid follicle cell activation. These effects were restricted to females. Female rats also showed increased absolute liver weights (22.9 mkd at 20%) and induction of T4-glucuronyl transferase (4.1 mkd at 10%), suggesting that aberrant metabolization of T4 triggers feedback activation of the thyroid hormone system. These effects were accompanied by possibly secondary effects, including increased cholesterol (7.4 mkd at 10%), increased tibial bone mineral density (> 49 mkd at 10%), both in females, and decreased splenocyte counts (0.3-6.3 mkd at 20%; only evaluated in males). Overall, female rats appeared to be more sensitive to HBCD than male rats, and an overall BMDL is proposed at 1.6 mkd, based on a 10% increase of the thyroid weight, which was the most sensitive parameter in the sequence of events.
van der Ven
Leo T M
LT
Laboratory for Toxicology, Pathology and Genetics, National Institute of Public Health and the Environment, 3720 BA Bilthoven, The Netherlands. l.van.der.ven@rivm.nl
Verhoef
Aart
A
van de Kuil
Ton
T
Slob
Wout
W
Leonards
Pim E G
PE
Visser
Theo J
TJ
Hamers
Timo
T
Herlin
Maria
M
Håkansson
Helen
H
Olausson
Hanna
H
Piersma
Aldert H
AH
Vos
Josephus G
JG
D000284:Administration, Oral; D000818:Animals; D015519:Bone Density / Q000187:drug effects; D002452:Cell Count; D004305:Dose-Response Relationship, Drug; D052244:Endocrine Disruptors / Q000145:classification / Q000633:toxicity*; D005260:Female; D014453:Glucuronosyltransferase / Q000096:biosynthesis; D006842:Hydrocarbons, Brominated / Q000145:classification / Q000633:toxicity*; D008099:Liver / Q000187:drug effects / Q000473:pathology; D008297:Male; D009929:Organ Size / Q000187:drug effects; D010902:Pituitary Gland / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D051381:Rats; D017208:Rats, Wistar; D018570:Risk Assessment; D013154:Spleen / Q000187:drug effects / Q000473:pathology; D013961:Thyroid Gland / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D013972:Thyrotropin / Q000378:metabolism; D013977:Tibia / Q000187:drug effects / Q000378:metabolism; D018675:Toxicity Tests
D052244:Endocrine Disruptors; D006842:Hydrocarbons, Brominated; C089796:hexabromocyclododecane; D013972:Thyrotropin; C117189:thyroxine-UDP-glucuronosyltransferase; D014453:Glucuronosyltransferase